CureVacCVAC
CVAC
About: CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Employees: 1,088
0
Funds holding %
of 7,310 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
29% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 21
15% more call options, than puts
Call options by funds: $329K | Put options by funds: $286K
11% more funds holding
Funds holding: 75 [Q4 2024] → 83 (+8) [Q1 2025]
0.01% more ownership
Funds ownership: 3.5% [Q4 2024] → 3.51% (+0.01%) [Q1 2025]
18% less capital invested
Capital invested by funds: $26.6M [Q4 2024] → $21.8M (-$4.78M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
8%
downside
Avg. target
$6.83
25%
upside
High target
$10
83%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
UBS Eliana Merle | 1%upside $5.50 | Neutral Downgraded | 26 Jun 2025 |
Jefferies Roger Song | 8%downside $5 | Hold Downgraded | 13 Jun 2025 |
JMP Securities Roy Buchanan | 83%upside $10 | Market Outperform Reiterated | 28 May 2025 |
Financial journalist opinion
Based on 11 articles about CVAC published over the past 30 days
Neutral
Accesswire
1 week ago
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.
Positive
Zacks Investment Research
1 week ago
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
Neutral
GlobeNewsWire
1 week ago
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CureVac N.V. (NASDAQ: CVAC ) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Is it a fair deal?
Neutral
GlobeNewsWire
2 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Negative
Investopedia
3 weeks ago
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow Jones Industrial Average was lower.
Positive
Schaeffers Research
3 weeks ago
CureVac Stock Soars on BioNTech Buyout
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
Positive
Benzinga
3 weeks ago
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
Positive
Proactive Investors
3 weeks ago
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.
Neutral
Business Wire
3 weeks ago
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Halper Sadeh encourages CureVac shareholders to click here to learn more a.
Positive
Barrons
3 weeks ago
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
CureVac stock soared 29% $5.26 in premarket trading immediately following the news.
Charts implemented using Lightweight Charts™